UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes

BMC infectious diseases, 2013-01, Vol.13 (1), p.29-29, Article 29

2013

Volltextzugriff (PDF)

Review of the basic and clinical pharmacology of sulfobutylether-β-cyclodextrin (SBECD)

Journal of pharmaceutical sciences, 2010-08, Vol.99 (8), p.3291-3301

2010

Volltextzugriff (PDF)

Fosmanogepix Therapy of Disseminated Fusarium Infection

Clinical infectious diseases, 2023-09, Vol.77 (6), p.848-850

2023

Volltextzugriff (PDF)

Combination antifungal therapy for invasive aspergillosis: a randomized trial

Annals of internal medicine, 2015-01, Vol.162 (2), p.81

2015

Volltextzugriff (PDF)

Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group

Clinical infectious diseases, 2015-03, Vol.60 (5), p.713-720

2015

Volltextzugriff (PDF)

Good Outcomes in Therapy of Fusariosis Depend on Both an Effective Drug and the Host

Clinical infectious diseases, 2024-01, Vol.79 (2), p.572

2024

Volltextzugriff (PDF)

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantation

British journal of haematology, 2011-11, Vol.155 (3), p.318-327

2011

Volltextzugriff (PDF)

Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign

Clinical infectious diseases, 2007-02, Vol.44 (3), p.373-379

2007

Volltextzugriff (PDF)

Voriconazole Treatment for Less-Common, Emerging, or Refractory Fungal Infections

Clinical infectious diseases, 2003-05, Vol.36 (9), p.1122-1131

2003

Volltextzugriff (PDF)

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis

Critical care (London, England), 2011-01, Vol.15 (5), p.R253-R253

2011

Volltextzugriff (PDF)

Ocular Manifestations of Candidemia

Clinical infectious diseases, 2011-08, Vol.53 (3), p.262-268

2011

Volltextzugriff (PDF)

Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome

BMC infectious diseases, 2011-09, Vol.11 (1), p.261-261, Article 261

2011

Volltextzugriff (PDF)

Early Serum Galactomannan Trend as a Predictor of Outcome of Invasive Aspergillosis

Journal of Clinical Microbiology, 2012-07, Vol.50 (7), p.2330-2336

2012

Volltextzugriff (PDF)

Early Proinflammatory Cytokines and C-Reactive Protein Trends as Predictors of Outcome in Invasive Aspergillosis

The Journal of infectious diseases, 2010-11, Vol.202 (9), p.1454-1462

2010

Volltextzugriff (PDF)

Changes in causes of death over time after treatment for invasive aspergillosis

Cancer, 2008-05, Vol.112 (10), p.2309-2312

2008

Volltextzugriff (PDF)

Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis

PloS one, 2014-02, Vol.9 (2), p.e90176

2014

Volltextzugriff (PDF)

Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients

The American journal of tropical medicine and hygiene, 2007-08, Vol.77 (2), p.350

2007

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children

Antimicrobial Agents and Chemotherapy, 2010-10, Vol.54 (10), p.4116-4123

2010

Volltextzugriff (PDF)

An Open-Label Comparative Pilot Study of Oral Voriconazole and Itraconazole for Long-Term Treatment of Paracoccidioidomycosis

Clinical infectious diseases, 2007-12, Vol.45 (11), p.1462-1469

2007

Volltextzugriff (PDF)

Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients

Clinical therapeutics, 2015-06, Vol.37 (6), p.1317-1328.e2

2015

Volltextzugriff (PDF)

Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome

Clinical infectious diseases, 2005-11, Vol.41 (10), p.1448-1452

2005

Volltextzugriff (PDF)

An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America

Mycoses, 2014-01, Vol.57 (1), p.12-18

2014

Volltextzugriff (PDF)

An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity

Journal of antimicrobial chemotherapy, 2013-07, Vol.68 (7), p.1655-1659

2013

Volltextzugriff (PDF)

Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study

Journal of clinical pharmacology, 2002-04, Vol.42 (4), p.395-402

2002

Volltextzugriff (PDF)

Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study

Journal of clinical pharmacology, 2002-04, Vol.42 (4), p.395-402

2002

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(46)

Sprache

Englisch
(46)
Japanisch
(10)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(33)
Humans
(32)
Female
(23)
Infectious Diseases
(23)
Male
(23)
Antifungal Agents - Therapeutic Use
(19)
Middle Aged
(19)
Adult
(16)
Biological And Medical Sciences
(16)
Voriconazole
(16)
Medical Sciences
(15)
Microbiology
(15)
Aged
(14)
Aspergillosis - Drug Therapy
(12)
Treatment Outcome
(12)
Immunology
(11)
Pyrimidines - Therapeutic Use
(11)
Triazoles - Therapeutic Use
(11)
Antifungal Agents - Administration & Dosage
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes

Review of the basic and clinical pharmacology of sulfobutylether-β-cyclodextrin (SBECD)

Fosmanogepix Therapy of Disseminated Fusarium Infection

Combination antifungal therapy for invasive aspergillosis: a randomized trial

Good Outcomes in Therapy of Fusariosis Depend on Both an Effective Drug and the Host

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantation

Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign

Voriconazole Treatment for Less-Common, Emerging, or Refractory Fungal Infections

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis

Ocular Manifestations of Candidemia

Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome

Early Serum Galactomannan Trend as a Predictor of Outcome of Invasive Aspergillosis

Early Proinflammatory Cytokines and C-Reactive Protein Trends as Predictors of Outcome in Invasive Aspergillosis

Changes in causes of death over time after treatment for invasive aspergillosis

Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis

Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients

Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children

An Open-Label Comparative Pilot Study of Oral Voriconazole and Itraconazole for Long-Term Treatment of Paracoccidioidomycosis

Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients

Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome

An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America

An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity

Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study

Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study

Suchergebnisse filtern